Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/109602
Title: | Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
Author: | Kawana-Tachikawa, Ai Llibre, Josep María Bravo, Isabel Escrig, Roser Mothe, Beatriz Puig, Jordi Puertas, Maria C. Martínez Picado, Francisco Javier Blanco, Julià Manzardo, Christian Miró Meda, José M. Iwamoto, Aikichi Pozniak, Anton L. Gatell, José M. Clotet, Bonaventura, 1953- Brander, Christian |
Keywords: | Cèl·lules T VIH (Virus) Antiretrovirals Resposta immunitària Genètica molecular T cells HIV (Viruses) Antiretroviral agents Immune response Molecular genetics |
Issue Date: | 27-Jan-2014 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0087334 |
It is part of: | PLoS One, 2014, vol. 9, num. 1, p. e87334 |
URI: | http://hdl.handle.net/2445/109602 |
Related resource: | https://doi.org/10.1371/journal.pone.0087334 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
641597.pdf | 844.68 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License